Language
English
Publication Date
8-1-2023
Journal
JCO Oncology Practice
DOI
10.1200/OP.22.00480
PMID
37207306
PMCID
PMC10424906
PubMedCentral® Posted Date
5-19-2023
PubMedCentral® Full Text Version
Post-print
Abstract
Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate with a topoisomerase I payload that targets the human epidermal growth factor receptor 2 (HER2). T-DXd is approved for patients with previously treated HER2-positive or HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/ISH-) metastatic/unresectable breast cancer (BC). In a second-line HER2-positive metastatic BC (mBC) population (DESTINY-Breast03 [ClinicalTrials.gov identifier: NCT03529110]), T-DXd demonstrated significantly improved progression-free survival (PFS) over ado-trastuzumab emtansine (12-month rate: 75.8%
Keywords
Humans, Female, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Immunoconjugates, Lung Diseases, Interstitial, Pneumonia
Published Open-Access
yes
Recommended Citation
Rugo, Hope S; Crossno, Christine L; Gesthalter, Yaron B; et al., "Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer" (2023). Faculty and Staff Publications. 1610.
https://digitalcommons.library.tmc.edu/baylor_docs/1610